HRP20120827T1 - Mutantni, dvostruko ciklizirani receptorski peptidi koji inhibiraju protutijela na adrenoceptor beta 1 - Google Patents

Mutantni, dvostruko ciklizirani receptorski peptidi koji inhibiraju protutijela na adrenoceptor beta 1 Download PDF

Info

Publication number
HRP20120827T1
HRP20120827T1 HRP20120827AT HRP20120827T HRP20120827T1 HR P20120827 T1 HRP20120827 T1 HR P20120827T1 HR P20120827A T HRP20120827A T HR P20120827AT HR P20120827 T HRP20120827 T HR P20120827T HR P20120827 T1 HRP20120827 T1 HR P20120827T1
Authority
HR
Croatia
Prior art keywords
cys
cyclic peptide
arg
asp
ala
Prior art date
Application number
HRP20120827AT
Other languages
English (en)
Croatian (hr)
Inventor
Roland Jahns
Valérie JAHNS
Martin Lohse
Viacheslav Nikolaev
Original Assignee
Julius-Maximilians-Universität Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius-Maximilians-Universität Würzburg filed Critical Julius-Maximilians-Universität Würzburg
Publication of HRP20120827T1 publication Critical patent/HRP20120827T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
HRP20120827AT 2007-08-24 2008-08-22 Mutantni, dvostruko ciklizirani receptorski peptidi koji inhibiraju protutijela na adrenoceptor beta 1 HRP20120827T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07016637 2007-08-24
PCT/EP2008/006932 WO2009027063A2 (en) 2007-08-24 2008-08-22 MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES

Publications (1)

Publication Number Publication Date
HRP20120827T1 true HRP20120827T1 (hr) 2012-11-30

Family

ID=40130559

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120827AT HRP20120827T1 (hr) 2007-08-24 2008-08-22 Mutantni, dvostruko ciklizirani receptorski peptidi koji inhibiraju protutijela na adrenoceptor beta 1

Country Status (13)

Country Link
US (1) US9062095B2 (enExample)
EP (3) EP2559698B1 (enExample)
JP (3) JP5248610B2 (enExample)
CN (2) CN103992406A (enExample)
AU (1) AU2008291296B2 (enExample)
CA (1) CA2697108C (enExample)
DK (1) DK2197900T3 (enExample)
ES (1) ES2391358T3 (enExample)
HR (1) HRP20120827T1 (enExample)
PL (1) PL2197900T3 (enExample)
PT (1) PT2197900E (enExample)
SI (1) SI2197900T1 (enExample)
WO (1) WO2009027063A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2559698B1 (en) * 2007-08-24 2014-11-12 Julius-Maximilians-Universität Würzburg Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies
WO2010086337A1 (en) * 2009-01-27 2010-08-05 Julius-Maximilians-Universität Würzburg Novel peptide-homologues for inhibiting beta1-adrenoceptor antibodies
DE102010018878B4 (de) 2009-04-30 2013-09-26 Julius-Maximilians-Universität Würzburg Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor
EP2402016A1 (en) * 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
US20140273015A1 (en) 2011-06-10 2014-09-18 Corim- Mun Gmbh BINDING COMPOUNDS TO HUMAN Beta 1-ADRENORECEPTOR (Beta 1-AR) AND THEIR USE IN MEASUREMENT OF AUTO-ANTI- Beta 1-AR ANTIBODIES
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
JPWO2015022953A1 (ja) * 2013-08-14 2017-03-02 国立大学法人 長崎大学 血液脳関門障害改善剤
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN108218963B (zh) * 2018-01-19 2020-10-13 首都医科大学 一种环肽及其制备方法和用途
EP3938403A1 (en) * 2019-03-14 2022-01-19 F. Hoffmann-La Roche AG Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP4217402A1 (en) * 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of autoantibody-mediated conditions
CN112266330B (zh) * 2020-10-15 2023-02-24 长沙博源医疗科技有限公司 一种甲氧基肾上腺素衍生物、免疫原、抗甲氧基肾上腺素特异性抗体及其制备方法与应用
WO2023028590A1 (en) * 2021-08-27 2023-03-02 Yale University Molecular degraders of extracellular proteins
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
KR20020047177A (ko) * 1999-09-21 2002-06-21 아피나 이문테히닉 게엠베하 확장성 심근질환을 유발하는 자동항체를 제거하기 위한펩티드
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
WO2001083693A2 (en) * 2000-04-28 2001-11-08 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
CN1988914A (zh) * 2001-08-23 2007-06-27 西兰制药公司 胞间通讯易化化合物的新医学用途
US7041790B2 (en) * 2002-03-26 2006-05-09 Dyax Corp. Fibrinogen binding moieties
US20080206264A1 (en) * 2003-02-04 2008-08-28 New York University Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
EP1536020A1 (en) 2003-11-26 2005-06-01 Bayerische Julius-Maximilians-Universität Würzburg Means and methods for optical determination of cAMP in vitro and in vivo
WO2006103101A2 (en) * 2005-03-31 2006-10-05 Julius-Maximilians-Universität Würzburg MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
EP2559698B1 (en) * 2007-08-24 2014-11-12 Julius-Maximilians-Universität Würzburg Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies

Also Published As

Publication number Publication date
CN103992406A (zh) 2014-08-20
AU2008291296B2 (en) 2014-02-06
CN101835793A (zh) 2010-09-15
ES2391358T3 (es) 2012-11-23
WO2009027063A2 (en) 2009-03-05
PL2197900T3 (pl) 2012-12-31
CN101835793B (zh) 2014-04-23
JP2013138679A (ja) 2013-07-18
EP2197900B9 (en) 2013-01-09
EP2559698B1 (en) 2014-11-12
JP2010536356A (ja) 2010-12-02
US9062095B2 (en) 2015-06-23
SI2197900T1 (sl) 2012-11-30
EP2497777A2 (en) 2012-09-12
DK2197900T3 (da) 2012-10-22
US20100209445A1 (en) 2010-08-19
WO2009027063A3 (en) 2009-07-23
EP2559698A2 (en) 2013-02-20
EP2559698A3 (en) 2013-03-06
AU2008291296A1 (en) 2009-03-05
CA2697108C (en) 2018-05-22
CA2697108A1 (en) 2009-03-05
HK1176363A1 (en) 2013-07-26
JP2013176369A (ja) 2013-09-09
PT2197900E (pt) 2012-10-24
JP5248610B2 (ja) 2013-07-31
EP2497777A3 (en) 2012-10-10
EP2197900A2 (en) 2010-06-23
EP2197900B1 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
HRP20120827T1 (hr) Mutantni, dvostruko ciklizirani receptorski peptidi koji inhibiraju protutijela na adrenoceptor beta 1
JP2010536356A5 (enExample)
KR101794781B1 (ko) 펩타이드계 ｇｌｐ－２ 작용제
HUT70459A (en) Analogs of pth
HU211348A9 (en) Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
NZ231936A (en) Insulin analogues with lys or arg in position b28, and pharmaceutical compositions
JP2020528743A5 (enExample)
NZ230384A (en) Peptides having neuropeptide y agonist activity
EP0647656B1 (en) Motilin-like polypeptides that inhibit gastrointestinal motor activity
CA2020838C (en) Hemoregulatory peptides
Kozawa et al. Isolation of four novel tachykinins from frog (Rana catesbeiana) brain and intestine
CN110678550A (zh) 长效肾上腺髓质素衍生物
US8440611B2 (en) Analogues of neuropeptide Y having at least one synthetic amino acid substitution
WO2011060613A1 (zh) 人α-防御素5突变体多肽及其制备方法和应用
KR20120052274A (ko) 경점막 흡수성을 가진 모틸린 유사 펩타이드 화합물
JP2512638B2 (ja) 安定化された効力のあるｇｒｆアナログ
CA3021231A1 (en) Pegylated bioactive peptides and uses thereof
AU609878B2 (en) Cyclic grf-analogs
JP2002539829A5 (enExample)
JP2012529423A5 (enExample)
JP2021531246A5 (enExample)
KR101393715B1 (ko) 펩타이드 구조물용 아미노산 대체물
KUROSAWA et al. Structure-activity relationships of neuromedin U. III. Contribution of two phenylalanine residues in dog neuromedin U-8 to the contractile activity
DE69312698T2 (de) Trizyklische tachikinin-antagonisten, deren herstellung und diese enthaltende pharmazeutische präparate
CN112029000A (zh) 鸭干扰素α融合蛋白在制备抗鸭1型肝炎病毒的药物中的用途